Despite extensive clinical trials for AD treatment, no success has been reported until the most recent anti-Aβ antibody trial and a tau-targeting antisense oligonucleotide (MAPTRx) trial that showed promising response in some patients with significant side effect in others (Mummery et al., 2023; van Dyck et al., 2023). This evidence concerns the gene MAPT and Alzheimer disease.